Figure 1. DISARM design and validation.

(A) Adapted IC₅₀ data (15) for NSCLC cell lines treated with the EGFR inhibitors erlotinib and osimertinib, the latter of which is effective in instances of EGFR T790M erlotinib resistance mutations. (C) DISARM-generated 2×2 plot for erlotinib (reference) and osimertinib (candidate) pair, in which DISARM accurately selects osimertinib as an effective agent in erlotinib-resistant NSCLC. Each black dot in 2×2 plot indicates a specific cell line. (D) Similarly, adapted IC₅₀ data for CML cell lines (16) treated with the BCR-ABL inhibitors dasatinib (reference) and ponatinib (candidate), the latter of which is an effective therapy in instances of BCR-ABL T315I resistance mutations. (E) DISARM correctly selects ponatinib as an effective therapy for dasatinib-resistant CML. (B-E) IC₅₀ and log10(IC₅₀) values are expressed in nanomolar (nM) concentration.